Interactive Brokers shares jump as it secures spot in S&P 500
SOUTH SAN FRANCISCO – Veracyte, Inc. (NASDAQ: VCYT), a global cancer diagnostics company valued at $2.38 billion with impressive revenue growth of 23.46% over the last twelve months, announced today that its Decipher Prostate Genomic Classifier data will now be accessible through a specialized database released by the National Cancer Institute’s (NCI) Surveillance, Epidemiology, and End Results (SEER) Program. According to InvestingPro analysis, the company maintains strong financial health with a "GREAT" overall score. This integration is expected to provide researchers with valuable insights by correlating genomic test results with a range of patient outcomes and demographic information.
The SEER Program, recognized as a comprehensive source of U.S. cancer statistics, has incorporated data from over 560,000 prostate cancer cases diagnosed between 2010 and 2018. The Decipher Prostate test, which has been available since 2013 for radical prostatectomy specimens and since 2016 for biopsy tissue, assists physicians in personalizing treatment for prostate cancer patients by predicting the risk of metastasis. This innovative approach has contributed to Veracyte’s robust gross profit margin of 69.48% and strong market position.
Philip Febbo, M.D., Chief Scientific Officer and Chief Medical Officer at Veracyte, expressed enthusiasm over the collaboration with the NCI SEER Program, anticipating that it will open numerous research avenues that could ultimately benefit patients. He also emphasized Veracyte’s dedication to advancing cancer understanding through clinical evidence.
The Decipher Prostate Genomic Classifier, a 22-gene test developed through RNA whole-transcriptome analysis and machine learning, has been validated in over 85 studies encompassing more than 200,000 patients. Its clinical utility is recognized with a Level I evidence status and inclusion in the NCCN Guidelines for prostate cancer risk stratification. The company’s strong financial position is reflected in its exceptional liquidity, with a current ratio of 4.73. For detailed financial analysis and additional insights, visit InvestingPro, where you’ll find comprehensive research reports and expert analysis on Veracyte and 1,400+ other top stocks.
Veracyte’s mission is to transform cancer care globally by providing clinicians with actionable insights during critical decision-making moments in cancer diagnosis and treatment. The company’s diagnostics platform leverages genomic and clinical data, bioinformatics, AI, and an evidence-generation engine to support test reimbursement, guideline inclusion, and ongoing innovation.
This announcement is based on a press release statement, and the information regarding the SEER database and Decipher Prostate Genomic Classifier can be verified independently.
In other recent news, Veracyte, Inc. has reported significant developments that investors may find noteworthy. The company announced a strong financial performance for the fourth quarter of 2024, with earnings per share (EPS) reaching $0.36, significantly surpassing the forecast of $0.10. Quarterly revenue also exceeded expectations, coming in at $118.6 million. Despite this strong performance, the company’s stock experienced a decline, which some attribute to strategic uncertainties and potential restructuring costs in its French subsidiary.
Analysts from Needham have maintained a Buy rating for Veracyte, with a price target of $51.00, citing the company’s robust fourth-quarter performance and strong growth in its Decipher and Afirma products. Guggenheim Securities also adjusted its outlook, reducing the price target to $37.00 while maintaining a Buy rating, reflecting a change in the valuation multiple used for the company’s estimated 2026 sales. Craig-Hallum initiated coverage with a Buy rating and a $45.00 price target, emphasizing Veracyte’s market-leading products and strong financial metrics.
Veracyte has not provided full 2025 revenue guidance, citing evaluations of its French subsidiary’s ownership, but it did project testing revenue that exceeds consensus estimates. The company is also focused on launching a metastatic technical assessment for its DECIPHER test and expanding its MRD platform in muscle-invasive bladder cancer. These developments underscore Veracyte’s strategic initiatives and market positioning, as highlighted by various analyst firms.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.